A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

NCT06993792 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

1200

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity
Overweight
Type 2 Diabetes

Interventions

DRUG: Orforglipron
DRUG: Placebo

Sponsor

Eli Lilly and Company